Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
The Ministry of Health, Labor and Welfare (MHLW) is working to forge a cold chain scheme for the delivery of mRNA-based COVID-19 vaccines in Japan, with the plan to secure 3,000 freezers for storage at minus 70 degrees Celsius and…
To read the full story
Related Article
- MHLW Unveils Overview of COVID-19 Vaccine Distribution Scheme in Japan
December 11, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
REGULATORY
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…